NovaCardia
Company

Last deal

$18.M

Amount

Series B

Stage

06.04.2007

Date

4

all rounds

$88.M

Total amount

General

About Company
NovaCardia Inc. is a pharmaceutical company that develops drugs to treat cardiovascular diseases.

Related to

Merck Sharp & Dohme Sweden AB

Merck Sharp & Dohme Sweden AB

Merck is a biopharmaceutical company that develops and provides innovative medicines and vaccines to save and improve lives globally.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Kenilworth, NJ, USA

total rounds

2

total raised

$5.59M

count Of Investments

21

count Of Exists

4

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2001

Operating Status

Closed

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company is dedicated to improving patient care by creating and marketing new small molecule drugs. NovaCardia has extensive experience in cardiovascular drug development and is initially focusing on the acute cardiac care market. In addition to its clinical-stage pharmaceuticals, the company is also working on an oral formulation of KW-3902 to treat chronic congestive heart failure.
Contacts

Phone number

Social url